Synthesis and Biological Evaluation of Novel Fused [1,2,3]Triazolo[4',5':3,4] pyrrolo[2,1-f]purines as Potent Anti-Proliferative Agents

In search of the best anticancer agents, a series of novel fused [1,2,3]triazolo[4',5':3,4] pyrrolo[2,1-f]purine derivatives in one vessel was synthesized using 8-bromo-1,3-dimethyl-7-(prop-2-yn-1-yl)-1H-purine-2,6(3H,7H)-dione and various arylazides. The newly synthesized derivatives were evaluated for their in vitro anti-proliferative activity against four human cancer cell lines (MCF-7, HeLa, A-549 and U-87MG). 3-(3,5-dichlorophenyl)-5,7-dimethyl-7,10-dihydro-[1,2,3]triazolo[4',5':3,4]pyrrolo[2,1-f]purine-6,8(3H,5H)-dione and 5,7-dimethyl-3-(4-nitrophenyl)-3,10-dihydro-[1,2,3]triazolo[4',5':3.4]pyrrolo[2,1-f]purine-6,8 (5H,7H)-dione are showed stronger activity against MCF-7 and A-549 with IC50 values ranging from 11.5 ± 0.64 to 15.3 ± 0.81 μM, which are comparable to the standard drug doxorubicin. Molecular docking studies have also been conducted to complement the experimental results.